

| CAS No: | 5266-20-6 |
| Name: | Lithium Orotate |
| EINECS: | 226-081-4 |
| Formula | C5H5LiN2O4 |
| Weight | 164.05 |
| Brand Name | Look Chemical |
| Place of Origin | China |
| Other Names: | Orotic Acid Lithium Salt Monohydrate; Vitamin B13; Orotatory acid |
| Type: | APIs; Organic raw materials |
| Product Model: | LC-5266-20-6 |
| Shelf Life | 3 Years |
| Usage | Preparation of antitumor composition |
| Form | Powder |
Orotatory acid is also known as vitamin B13. It is obtained from water as white, shiny needle-shaped crystals or crystalline powder, odorless and sour. Melting point 345-346℃. It is insoluble in cold water and ethanol, slightly soluble in hot water. It reacts with hydrogen peroxide and concentrated hydrochloric acid to form 5-chlorouracil-4-carboxylic acid. It can be obtained by condensing diethyl oxalate with ethyl acetate to diethyl butyrate, cyclizing with urea and then hydrolyzing. It is used in medicine to treat jaundice and general liver dysfunction.
Lithium is a soft, silvery-white metal that belongs to the alkali metal family of chemical elements. Lithium exists in more than 50 compounds and has two stable isotopes, lithium-6 and lithium-7. It is the lightest metal and the lowest density solid element. Lithium is highly reactive and flammable, although it is the least reactive alkali metal. Since lithium has only a single valence electron, which is easily lost to form a cation, it is a good conductor of heat and electricity. Lithium also has the highest electrochemical potential of all metals. Due to its high reactivity, lithium does not exist in nature in a free state. Instead, lithium naturally occurs only in compositions, usually as ions in nature, such as lithium carbonate. Therefore, lithium metal can only be obtained by extracting lithium from lithium-containing compounds.
In 1949, Cade published the article “Lithium for the Treatment of Psychomotor Excitement”, which officially introduced lithium into psychiatric clinics for the treatment of mania. The discovery of lithium salts pioneered psychopharmacology, but lithium salts have certain toxic side effects, which limit their widespread use. In 1957, Australian doctors Noack and Trautner proposed the importance of effective blood lithium concentration and blood lithium monitoring for safety. In the following years, the introduction of blood lithium monitoring greatly reduced the occurrence of lithium salt toxicity and side effects. Therefore, lithium has been widely used in Europe since 1965. In 1970, the US Food and Drug Administration (FDA) officially approved the use of lithium in the United States. my country also used lithium to treat mania in the early 1970s. So far, lithium has been widely used in psychiatric clinics by the world psychiatric community, but so far, there has been no report on the use of lithium salts such as lithium orotate in targeted anti-osteosarcoma treatment. Lithium orotate is the lithium salt of orotic acid, CAS 5266-20-6, molecular formula C5H5LiN2O5, molecular weight 180.04500, melting point 300ºC. Lithium orotate has a certain role in targeted anti-osteosarcoma treatment.
| Item | Specification |
| Product Name | Lithium Orotate |
| CAS No. | 5266-20-6 |
| Appearance | White crystalline powder |
| Shelf Life | 2 years |
| Packing | 1kg/bag,25kg/bag or as your requirements |
Lithium orotate is used to prepare anti-tumor compositions. Experiments have shown that lithium preparations have significant in vivo and in vitro anti-osteosarcoma effects, which may be achieved by phosphorylating GSK-3β to inhibit its function. Combined use with classic chemotherapy drugs such as doxorubicin significantly enhances its tumor-killing effect and is a potential targeted therapeutic drug for osteosarcoma. Lithium salts can be lithium chloride (LiCl), lithium carbonate, lithium sulfate, lithium citrate, lithium orotate, and other lithium salts that can or have been used pharmaceutically. A study provides a pharmaceutical composition of lithium preparations, which includes lithium salts and pharmaceutically acceptable carriers or excipients, such as isotonic agents such as NaCl and glucose for powder injections, and water and powder injection excipients for injections; oral preparations include but are not limited to adhesives, disintegrants, lubricants, glidants, etc. The dosage form of the pharmaceutical composition is powder injection or injection, or it can be an oral preparation, and the oral preparation can be an oral liquid, tablet, capsule, granule, etc. Disintegrants for preparing tablets, capsules, and granules can be dry starch, sodium hydroxymethyl starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose (L-HPC), hydroxypropyl methyl cellulose (HPMC), and polyvinyl pyrrolidone (PVP). Adhesives can be starch, ethanol, dextrin, sodium hydroxymethyl cellulose, lubricants, glidants can be talcum powder, micro-powder silica gel, magnesium stearate, and other excipients known in the art can also be used.
When lithium preparations are used in drugs for targeted treatment of osteosarcoma, the following treatment regimen is usually adopted: add isotonic regulators such as NaCl, glucose, etc., prepare powder injections or injections, intramuscular or intravenous injections of 10-70 mg/time (in terms of lithium), once every 8 to 24 hours, and a course of treatment of 7 to 14 days. Oral dosage forms can also be used, but the dose should be doubled at the same time. It can also be made into compound preparations with other anti-tumor drugs, such as compound preparations with doxorubicin, which can achieve enhanced or even synergistic therapeutic effects.
Lithium orotate is used to prepare drugs for the treatment of CNS diseases.
The treatment process involves contacting the in vitro differentiated choroid plexus (CP) cells in the one or more capsules with a choroid plexus inducer at the same time or after administration, and the choroid plexus inducer includes one or more agents selected from the following:
(a) Wnt signaling pathway agonist, (b) GSK3β inhibitor, (c) β-catenin activator, (d) antioxidant and (e) 1,25-dihydroxyvitamin D3. Wherein the Wnt signaling pathway agonist is selected from WAY-316606 (SFRP inhibitor), IQ1 (PP2A activator), QS11 (ARFGAP1 activator), (hetero)aryl pyrimidine or 2-amino-4-[3,4-(methylenedioxy)benzyl-amino]-6-(3-methoxyphenyl)pyrimidine, Norrin, R-spondin-1, R-spondin-2, R-spondin-3, R-spondin-4; (2) the GSK3β inhibitor is selected from SB-216763, BIO (6-bromoindirubin-3′-oxime), lithium chloride, lithium carbonate, lithium citrate, lithium orotate, etc.
1. Certificate Of Analysis (COA)
2. Material Safety Data Sheet (MSDS)
3. Route of synthesis (ROS)
4. Method of Aanlysis (MOA)
5. Nuclear Magnetic Resonance (NMR)
6. Packing pictures and loading video before loading
7. Free Sample
8. Factory audit
As an experienced lithium orotate manufacturer and supplier, Look Chemical is committed to producing and selling high quality products.
We cooperate and trade with 6000+ factories around the world, and our high-quality products and excellent services make us enjoy a high reputation internationally.
As lithium orotate supplier, Look Chemical provides supply chain solutions to partners and customers in a wide range of industries. We offer competitive pricing and quality products.
If you have a demand for this product, please contact our company’s sales staff, we will provide you with a solution in the shortest time.
1. ≤50kg, Express delivery recommended, usually called as DDU service;
2. ≤500kg, Air shipping recommended, usually called as FOB, CFR, or CIF service;
3. >500kg, sea shipping recommended, usually called as FOB, CFR, or CIF service;
4. For high value products, please select air shipping and express delivery for safe.